Vifor Pharma reports sustained growth in 2021
Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment Iron franchise – Ferinject® / Injectafer® sales up 20.1% at CER reflecting strong recovery on improved pati